TY - JOUR
T1 - New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance
AU - Syue, Ling Shan
AU - Chen, Yen Hsu
AU - Ko, Wen Chien
AU - Hsueh, Po Ren
N1 - Publisher Copyright:
© 2016 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
PY - 2016/4
Y1 - 2016/4
N2 - The continuing increase in multidrug-resistant organisms (MDROs) worldwide has created new challenges in treating complicated intra-abdominal infections (cIAIs). A number of novel antimicrobial agents have been developed against resistant pathogens. To target extended-spectrum β-lactamase (ESBL)-producing pathogens, novel β-lactam antibiotics, such as ceftolozane/tazobactam, ceftazidime/avibactam, aztreonam/avibactam, imipenem/relebactam and S-649266, are antimicrobial alternatives for cIAIs. Two new drugs, eravacycline and plazomicin, have activity against Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae, carbapenem-resistant Acinetobacter baumannii and ESBL-producers. New lipoglycopeptides and oxazolidinones provide feasible options against resistant Gram-positive pathogens. These novel antimicrobials may play a role in improving the clinical outcomes of cIAIs caused by MDROs.
AB - The continuing increase in multidrug-resistant organisms (MDROs) worldwide has created new challenges in treating complicated intra-abdominal infections (cIAIs). A number of novel antimicrobial agents have been developed against resistant pathogens. To target extended-spectrum β-lactamase (ESBL)-producing pathogens, novel β-lactam antibiotics, such as ceftolozane/tazobactam, ceftazidime/avibactam, aztreonam/avibactam, imipenem/relebactam and S-649266, are antimicrobial alternatives for cIAIs. Two new drugs, eravacycline and plazomicin, have activity against Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae, carbapenem-resistant Acinetobacter baumannii and ESBL-producers. New lipoglycopeptides and oxazolidinones provide feasible options against resistant Gram-positive pathogens. These novel antimicrobials may play a role in improving the clinical outcomes of cIAIs caused by MDROs.
UR - http://www.scopus.com/inward/record.url?scp=84961226195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961226195&partnerID=8YFLogxK
U2 - 10.1016/j.ijantimicag.2015.12.021
DO - 10.1016/j.ijantimicag.2015.12.021
M3 - Short survey
C2 - 27005457
AN - SCOPUS:84961226195
SN - 0924-8579
VL - 47
SP - 250
EP - 258
JO - International journal of antimicrobial agents
JF - International journal of antimicrobial agents
IS - 4
ER -